Brokerages forecast that Affimed NV (NASDAQ:AFMD) will report $1.15 million in sales for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Affimed’s earnings, with the highest sales estimate coming in at $1.74 million and the lowest estimate coming in at $560,000.00. Affimed reported sales of $1.48 million during the same quarter last year, which indicates a negative year-over-year growth rate of 22.3%. The firm is scheduled to issue its next quarterly earnings report on Thursday, March 29th.
According to Zacks, analysts expect that Affimed will report full year sales of $1.15 million for the current fiscal year, with estimates ranging from $1.80 million to $10.00 million. For the next fiscal year, analysts anticipate that the company will post sales of $17.64 million per share, with estimates ranging from $2.28 million to $33.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Affimed.
Separately, Oppenheimer reaffirmed a “hold” rating on shares of Affimed in a report on Friday, November 24th.
Shares of Affimed (AFMD) traded down $0.10 on Friday, reaching $2.20. The company’s stock had a trading volume of 353,459 shares, compared to its average volume of 936,214. Affimed has a 52-week low of $1.15 and a 52-week high of $2.85. The company has a debt-to-equity ratio of 0.14, a quick ratio of 6.39 and a current ratio of 6.43.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.